disc medicine shares added to fridays gains rising 8 to 4920 on monday as more analysts raised price targets following news of favorable preliminary results from a bitopertin clinical trial the stock reached a 52week high of 5495 its 52week low was 1180 on dec 28 on friday the company reported preliminary results from a phase 2 trial of bitopertin in patients with erythropoietic protoporphyria and xlinked protoporphyria rare diseases that result in severe reactions from exposure to sunlight shares rose 16 friday raymond james raised disc to strong buy from outperform and increased its price target to 75 from 50 morgan stanley maintained its overweight rating and raised its target to 56 from 37